Janux to Present Initial JANX011 Phase 1 Data at Virtual Event
Janux Therapeutics said CEO David Campbell will present initial Phase 1 clinical data for JANX011 in healthy volunteers at a virtual event on November 9, 2026, at 8:30 a.m. ET.
Janux Therapeutics said CEO David Campbell will present initial Phase 1 clinical data for JANX011 in healthy volunteers at a virtual event on November 9, 2026, at 8:30 a.m. ET.